Company: BLLN
Filing Date: 2025-10-17
Form Type: S-1/A
Source: 0001193125-25-242632
Chunk: 205

Company: BillionToOne, Inc.
Filing Date: 2025-10-17
Form: S-1/A
Chunk 205
---
 automates labor-intensive clerical tasks. This allowed us to redeploy our laboratory personnel to higher impact areas. As a technology-forward organization, we have decreased our Overall Cost Per Test by more than 21% in the 24 months ended June 30, 2025, in part by deploying automation and AI. While our current laboratory space is already sufficient for at least four times more growth, our process engineering and automation teams continue to work on creative solutions to further scale our laboratory capacity and decrease our COGS. 141

IP and know-how Our smNGS platform is protected by a suite of over 50 patents and proprietary technological know-how.Our patented technologies differentiate us from our competitors and support improved quality controls, enable nimble product iteration, and drive rational assay design that allow us to build novel products with attractive gross margin. We have multiple issued patents for our core technologies and our ancillary technology in the United States and internationally. Our core patents cover various approaches to using synthetic molecules to provide accurate counting of target molecules, which is our QCT technology, as well as protecting the following technologies:

| - |     | Dilution tagging is a novel method to quantify the abundance of targeted DNA molecules across a dynamic range of many orders of magnitude. This technology enables low-cost                                 
 sequencing of cfDNA samples with rare sequences without the loss of quantitative information. For example, this can reduce sequencing costs by 10-50x for sequencing intensive applications, such as immune 
 receptor repertoire profiling and single cell RNA sequencing.                                                                                                                                               |

| - |     | Spike-in technology refers to synthetic DNA controls custom-made for each assay and added to every patient sample. These DNA controls enable the calculation of relative 
 abundance of targeted DNA molecules at a low cost.                                                                                                                       |

| - |     | qSanger technology combines spike-in technology with custom-built, proprietary signal processing and applies it to Sanger sequencing and capillary electrophoresis, bringing 
 the power of quantification to previously qualitative technologies. This approach brings NGS-level precision to easy-to-deploy                                               
 technologies and enables their use as low-cost and high-throughput diagnostic tools.                                                                                         |

Beyond these patented technologies, we have developed substantial proprietary techniques and know-howthroughout our organization that are critical to our R&D and commercial success. We protect our IP through a comprehensive strategy including patents, trademarks, copyrights, trade secrets, confidentiality agreements, and other contractual protections. For further details on our IP portfolio, including issued and pending patents, see the section titled “Intellectual property